drugset / Trial / NCT07674771
Response With Interim PSMA PET in Metastatic Castration-sensitive Prostate Cancer for Optimization of Adaptive Metastasis-directed Radiotherapy Delivery
Phase 0
Not yet recruiting
30 enrolled
University of Texas Southwestern Medical Center
Telix Pharmaceuticals (Innovations) Pty Limited · collabVarian, a Siemens Healthineers Company · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to characterize the reduction in PSMA-avid tumor volume and metastasis-directed radiotherapy treatment intensity facilitated by PET PSMA-response adapted SABR for poly-metastatic castration sensitive prostate cancer.
Timeline
- Start
- 2026-07-15
- Primary completion
- 2029-06-15
- Completion
- 2029-06-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 68Ga-PSMA-11 | Diagnostic / imaging agent | — | Other |